

DIA Middle East Conference: A New Platform For Healthcare Advancement in the Region

The DIA Middle East Conference is a new platform created to promote dialogue and collaboration for regional healthcare advancement. DIA Middle East aims to be the key platform to promote dialogue, drive collaboration and advance solutions amongst the key stakeholders in the region – Health Authorities representatives, Industry leaders, Academia, Patients, among others – throughout the entire drug development lifecycle.

Since 1996, DIA has developed a number of initiatives in the Middle East region, being the Middle East Regulatory Conference (MERC), co-developed with the EFPIA Middle East Regulatory Network (MERN), the one with the biggest reach and relevance.



The Fairmont Riyadh

Developed in close collaboration with the Saudi Food and Drug Administration (SFDA), DIA Middle East's programme was designed to ignite discussions across 8 content tracks:

- Regulatory Innovation & Strategy (including Real-World Evidence use and regulatory frameworks for Innovative Therapies)
- Regulatory Convergence (including Reliance and Regulatory Systems Strengthening)
- CMC, Quality & Manufacturing (including Variations and Inspections)
- Safety & Pharmacovigilance
- Value & Access and Patient Engagement
- Innovation, Digital & Devices (including eCTD)
- Clinical Development and Operations
- Biologics & Biosimilars

The Steering Committee includes representatives from the various stakeholders in the region, ensuring the programme is equal parts broad, deep, and above all representative of the multiple realities within the region.

Discussions:

There is a deep focus on ensuring there is time and space for the most impactful discussions. Below are some of the highlights:

Middle East Townhall:

Senior leaders from all Health Authorities in the Middle East region will share their updates, best practices and experiences, together with examples of collaboration, work-sharing and reliance within and outside the region.

Saudi Townhall:

- The Saudi Townhall will reflect and highlight the efforts made by the Kingdom of Saudi Arabia to support and increase patients' access to innovative medicines, while sharing best practices with other stakeholders from the various Middle East countries.
- Being healthcare one of the key areas of focus of the Saudi Vision 2030 (including improving access to healthcare and increasing the efficiency of the healthcare system), this session will explore the goals and projects from the several entities to accomplish the Saudi Vision 2030 for healthcare, the pharma sector dynamics in Saudi Arabia, and the efforts made by the Kingdom to increase patients' access to medicines.

Exploring Main Barriers For Patients' Access To Medicines:

- Regulatory Systems supporting accelerated access to innovation
- Health equity, reducing health access inequalities & PPP Policy Shaping
- Access to Clinical Trials and Innovation: Making the region a hub for CTs while supporting R&D Innovation

WHO Townhall:

Regulatory systems strengthening activities have a key role to play in helping countries identify and address gaps, using the benchmarking tool and building capacity towards achieving a more stable maturity level (ML3 goal of WHA Resolution 67.20). The session will introduce the key elements of WHO's regulatory system strengthening and reliance program and discuss their impact and implementation.